Prime Medicine Inc. (PRME)
NASDAQ (NMS) NASDAQ (NMS) Primary Summary
Prime Medicine, Inc. (PRME) Discusses Liver Disease Franchise Strategy With Focus on Wilson Disease Transcript
Prime Medicine, Inc. ( PRME ) Discusses Liver Disease Franchise Strategy With Focus on Wilson Disease November 12, 2025 8:00 AM EST Company Participants Gregory Dearborn Allan Reine - CEO & Director Mohammed Asmal Conference Call Participants Michael Schilsky Maurice Raycroft - Jefferies LLC, Research Division Samantha Semenkow - Citigroup Inc., Research Division Troy Langford David Nierengarten - Wedbush Securities Inc., Research Division Yu He - H.C. Wainwright & Co, LLC, Research Division Silvan Tuerkcan - Citizens JMP Securities, LLC, Research Division Soumit Roy - JonesTrading Institutional Services, LLC, Research Division Presentation Gregory Dearborn Good morning, everyone, and welcome to Prime Medicine's virtual event to discuss our liver disease franchise and strategy focused on Wilson disease.
Prime Medicine, Inc. (PRME) Reports Q3 Loss, Lags Revenue Estimates
Prime Medicine, Inc. (PRME) came out with a quarterly loss of $0.32 per share versus the Zacks Consensus Estimate of a loss of $0.28. This compares to a loss of $0.44 per share a year ago.
Prime Medicine, Inc. (PRME) Reports Q2 Loss, Lags Revenue Estimates
Prime Medicine, Inc. (PRME) came out with a quarterly loss of $0.41 per share versus the Zacks Consensus Estimate of a loss of $0.36. This compares to a loss of $0.46 per share a year ago.
Prime Medicine Inc. (PRME) FAQ
What is the stock price today?
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
When is the next earnings date?
Has Prime Medicine Inc. ever had a stock split?
Prime Medicine Inc. Profile
| Biotechnology Industry | Healthcare Sector | Allan Reine CEO | NASDAQ (NMS) Exchange | 74168J101 CUSIP |
| US Country | 214 Employees | - Last Dividend | - Last Split | 20 Oct 2022 IPO Date |
Overview
Prime Medicine, Inc. is a biotechnology enterprise specialized in pioneering genetic therapies to combat a broad spectrum of diseases by harnessing the power of gene editing technology. Established in 2019, the company positions itself at the forefront of genetic medicine with its innovative approach to editing DNA sequences. Operating from its headquarters in Cambridge, Massachusetts, Prime Medicine is dedicated to realizing the potential of genetic correction and modification to treat conditions that have long been considered untreatable. The company has embarked on a significant collaboration with Cimeio Therapeutics, focusing on the development of Prime Edited Shielded-Cell & Immunotherapy Pairs, targeting genetic diseases, acute myeloid leukemia, and myelodysplastic syndrome.
Products and Services
- Prime Editors
- Collaborative Research Projects
At the core of Prime Medicine's offerings are the Prime Editors, a revolutionary gene editing tool. This technology combines a Prime Editor protein, which is a fusion of a Cas protein and a reverse transcriptase enzyme, with a pegRNA (prime editing guide RNA). The pegRNA is crucial as it not only directs the Prime Editor to a specific location within the genome but also supplies the template needed for executing the desired edit on the target DNA sequence. This sophisticated mechanism allows for precision in gene editing, paving the way for treatment strategies that could correct genetic mutations at their source.
Underpinning Prime Medicine's innovative technology is its strategic research collaboration with Cimeio Therapeutics. This partnership is primarily focused on the development of Prime Edited Shielded-Cell & Immunotherapy Pairs. These novel therapeutic strategies are designed to treat a range of conditions, from genetic diseases to cancers like acute myeloid leukemia and myelodysplastic syndrome. This collaboration highlights Prime Medicine's commitment to leveraging its technology in concert with other biotech entities to address complex medical challenges.
Contact Information
